Pneumocystis Infections¶
Chapter 227 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Pneumocystis jirovecii is a host-specific fungal pathogen causing severe pneumonia in immunocompromised hosts, particularly those with HIV/AIDS.
- Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line treatment for Pneumocystis pneumonia (PCP), with corticosteroids recommended for severe cases.
- CD4+ T-cell counts <200/ µ L are a key indicator for PCP risk in HIV patients, and prophylaxis is critical to prevent morbidity and mortality.
- Diagnosis relies on bronchoalveolar lavage (BAL) with methenamine silver stain or PCR, with imaging showing diffuse interstitial infiltrates.
- Complications include respiratory failure, pneumothorax, and immune reconstitution inflammatory syndrome (IRIS) in HIV patients.
1. DEFINITION & OVERVIEW¶
Pneumocystis is an opportunistic fungal pathogen causing pneumonia in immunocompromised hosts. Pneumocystis jirovecii is the species specific to humans, while P. carinii (rats) and P. oryctolagi (rabbits) are host-specific. The organism is now classified as a fungus, not a protozoan, and cannot be cultured in vitro.
Table 227-1: Treatment of Pneumocystis Pneumonia¶
| DRUG(S) | DOSE, ROUTE | ADVERSE EFFECTS |
|---|---|---|
| TMP-SMX | TMP (5 mg/kg) plus SMX (25 mg/kg) q6–8h PO or IV (2 double-strength tablets tid or qid) | Fever, rash, cytopenias, hepatitis, hyperkalemia |
| Clindamycin + Primaquine | Clindamycin 300–450 mg q6h PO or 600 mg q6–8h IV + Primaquine 15–30 mg qd PO | Hemolysis (G6PD deficiency), methemoglobinemia, neutropenia, rash |
| Pentamidine | 3–4 mg/kg qd IV | Hypotension, azotemia, cardiac arrhythmias, pancreatitis, dysglycemias, hypocalcemia, neutropenia, hepatitis |
| Atovaquone | 1500 mg qd PO (requires fatty meal) | Rash, fever, hepatitis |
1.1 Host Specificity¶
Humans are only infected by P. jirovecii, which is transmitted via respiratory route. Other species (e.g., P. carinii) do not infect humans. Pneumocystis has a unique tropism for the lung, with organisms inhaled into alveoli and proliferating in immunocompromised hosts.
1.2 Immune Evasion¶
Pneumocystis evades immune detection by forming cysts and trophozoites. Defects in cellular immunity (e.g., HIV, corticosteroids) or humoral immunity predispose to infection. CD4+ T cells are critical for host defense.
2. EPIDEMIOLOGY¶
PCP incidence rose with the AIDS epidemic, affecting ~80–90% of HIV patients with CD4+ T-cell counts <200/ µ L. Non-HIV-related immunosuppression (e.g., organ transplants, cancer) also contributes. Lower incidence in some countries may reflect competing infections (e.g., TB) or underdiagnosis.
2.1 Risk Factors¶
HIV infection, organ transplantation, hematologic malignancies, corticosteroid use, and immunosuppressive therapies (e.g., rituximab, alemtuzumab). Severe neutropenia and prolonged immunosuppression increase risk.
2.2 Demographics¶
Most common in immunocompromised individuals, particularly those with HIV/AIDS. In non-HIV populations, PCP is rare but can occur in congenital immunodeficiencies or post-transplant.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Pneumocystis is a host-specific fungus with a life cycle involving trophic forms, cysts, and precysts. Transmission occurs via respiratory route. Immune defects (e.g., HIV, corticosteroids) impair clearance, leading to pulmonary infection and systemic dissemination.
3.1 Immune Defects¶
Defects in CD4+ T-cell function and oxidative burst by phagocytes predispose to infection. HIV patients with CD4+ counts <200/ µ L are at highest risk. Non-HIV immunosuppression (e.g., chemotherapy) also increases susceptibility.
3.2 Pathogenesis¶
Pneumocystis proliferates in alveoli, causing proteinaceous exudates and alveolar damage. In immunocompromised hosts, it can disseminate to lungs, liver, spleen, and lymph nodes.
4. CLINICAL FEATURES¶
PCP presents as acute or subacute pneumonia with dyspnea, nonproductive cough, and progressive hypoxemia. Extrapulmonary manifestations (e.g., lymphadenopathy, splenomegaly) are rare. In HIV patients, IRIS may occur post-ART initiation.
4.1 Symptoms¶
Initial symptoms include dyspnea, chest tightness, and mild fever. Progression to severe hypoxemia, respiratory failure, and pneumothorax is common. Nonproductive cough and diffuse interstitial infiltrates on imaging are hallmark findings.
4.2 Complications¶
Pneumothorax, respiratory failure, and IRIS in HIV patients. Disseminated disease may involve liver, spleen, and lymph nodes, though rare.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include other fungal infections (e.g., Cryptococcus, Aspergillus), viral pneumonia, and bacterial pneumonia. Extrapulmonary manifestations may mimic other systemic fungal infections (e.g., invasive candidiasis).
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis relies on BAL with methenamine silver stain, PCR, or histopathology. Imaging shows diffuse interstitial infiltrates. Serologic tests (e.g., (1 → 3)- β -d-glucan) are not specific but may support diagnosis.
Table 227-2: Prophylaxis of Pneumocystis Pneumonia¶
| DRUG(S) | DOSE, ROUTE | COMMENTS |
|---|---|---|
| TMP-SMX | 1 tablet (double- or single-strength) qd PO | High hypersensitivity risk; rechallenge with dose escalation possible |
| Dapsone + Pyrimethamine + Leucovorin | Dapsone 50 mg qd PO + Pyrimethamine 50 mg weekly PO + Leucovorin 25 mg weekly PO | Leucovorin ameliorates cytopenias from pyrimethamine |
| Pentamidine | 300 mg monthly via Respirgard II nebulizer | Less effective than TMP-SMX; may cause bronchospasm |
| Atovaquone | 1500 mg qd PO (with fatty meal) | Alternative for TMP-SMX intolerance |
6.1 Diagnostic Methods¶
Bronchoalveolar lavage (BAL) with methenamine silver or Giemsa stain is the gold standard. PCR is highly sensitive but may detect colonization. Chest X-ray/CT shows diffuse ground-glass opacities and interstitial infiltrates.
6.2 Laboratory Findings¶
Elevated LDH and hypoxemia are common. Serum (1 → 3)- β -d-glucan levels may be elevated but lack specificity. Normal LDH does not rule out PCP.
7. MANAGEMENT & TREATMENT¶
TMP-SMX is first-line for PCP. Corticosteroids (e.g., prednisone) are used for severe cases. Alternatives include pentamidine, clindamycin-primaquine, and atovaquone. Prophylaxis is critical for HIV patients with CD4+ <200/ µ L.
7.1 First-Line Therapy¶
TMP-SMX (14 days for non-HIV patients, 21 days for others). Corticosteroids (e.g., prednisone 40 mg bid) are added for severe disease (e.g., PaO2 <70 mmHg).
7.2 Alternative Agents¶
Pentamidine (IV, 60 min infusion) or clindamycin-primaquine (oral). Atovaquone is used for mild disease or TMP-SMX intolerance. Echinocandins may have limited role in cyst forms.
7.3 Prophylaxis¶
TMP-SMX is the preferred prophylaxis for HIV patients with CD4+ <200/ µ L. Dapsone or aerosolized pentamidine may be used in non-HIV immunosuppressed patients.
8. PROGNOSIS & COMPLICATIONS¶
Untreated PCP is fatal. Mortality is reduced with TMP-SMX and corticosteroids. Complications include respiratory failure, pneumothorax, and IRIS in HIV patients. Prognosis depends on immune reconstitution and comorbidities.
8.1 Mortality¶
Mortality rates are ~10–20% with TMP-SMX and corticosteroids. Untreated PCP is invariably fatal. IRIS may occur in HIV patients post-ART initiation.
8.2 Long-Term Outcomes¶
Immune reconstitution after ART leads to improved prognosis. Persistent neutropenia or non-HIV immunosuppression worsens outcomes.
9. SPECIAL CONSIDERATIONS¶
Chemoprophylaxis is critical for HIV patients with CD4+ <200/ µ L. In non-HIV immunosuppressed patients, CD4+ counts <200/ µ L are a marker but not absolute. Monitoring for drug toxicity (e.g., renal dysfunction, neutropenia) is essential.
9.1 Pregnancy¶
TMP-SMX is safe in pregnancy. Prophylaxis is recommended for HIV-positive pregnant women with CD4+ <200/ µ L.
9.2 Pediatrics¶
PCP in children is rare but possible in immunocompromised hosts. Prophylaxis is indicated for high-risk pediatric patients.
10. KEY POINTS & CLINICAL PEARLS¶
- Pneumocystis jirovecii is the only human pathogen; no cross-species transmission.
- CD4+ T-cell counts <200/ µ L are a key indicator for PCP risk.
- TMP-SMX is first-line, with corticosteroids for severe cases.
- Prophylaxis is critical for HIV patients.
- Monitor for drug toxicity (e.g., renal dysfunction, neutropenia) with all therapies.